At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.
Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.
FOR IMMEDIATE RELEASE
Director of Communications
Office of University Communications
College of Pharmacy Partners with TNI BioTech to Develop New Drugs for Africa
WASHINGTON (May 21, 2013) Howard University College of Pharmacy has signed a multi-year agreement with TNI BioTech Inc., a Bethesda, Md., biotech firm that develops immunotherapy drugs to treat patients with chronic diseases, to assist in TNI BioTech's efforts to provide affordable health care and the development of pharmaceutical skills in Africa.
TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events
TNI BioTech, Inc., Bethesda, MD – (OTC PINK: TNIB), a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using its patented immunotherapy, issued a letter to its shareholders from CEO Noreen Griffin and the company's board of directors. The letter follows:
The board of directors of TNI BioTech, Inc. is very pleased to provide an update on the progress made over the last year. This update gives the company opportunity to provide detailed reviews of several key achievements, as well as share a brief outline of the steps being taken to maximize shareholder value over the coming months.
The company, as of May 15, 2013, filed its first Q1 2013 financials with the Securities and Exchange Commission and OTC markets. This milestone, in conjunction with the filing of a Form 10, allows the company to become fully reporting. While waiting for approval of its Form 10, the company will file the required documents to trade on the QX OTC market, providing improved transparency to the investment community.
TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant
Bethesda MD – TNI BioTech, Inc. (OTC PINK: TNIB) announced today the appointment of industry veteran, Dr. Joseph M. Fortunak, as a strategic consultant to the company. Dr. Fortunak is the former director and head of Global Chemical Development at Abbott Laboratories Corporation, where he managed more than 350 scientists and technical experts.
Dr. Fortunak spent 10 years at SmithKline Beecham (now part of GlaxoSmithKline) working in process chemistry and drug development. Dr. Fortunak worked for 8 years at DuPont Pharmaceuticals, rising to the level of executive director of chemical development. From 2000-2004, Dr. Fortunak then served as the head of Global Chemical Development for Abbott Labs. While in the industry, Dr. Fortunak made significant contributions to 15 new chemical entities for the treatment of HIV/AIDS, malaria, cancer, and various cardiovascular and central nervous system (CNS) indications. He also contributed to roughly 20 new generic drug launches.